|
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
|
09 January 2018 |
|
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
|
03 January 2018 |
|
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
|
12 December 2017 |
|
Novartis tender offer for Advanced Accelerator Applications commences
|
07 December 2017 |
|
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention
|
29 November 2017 |
|
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
|
27 November 2017 |
|
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
|
17 November 2017 |
|
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
|
13 November 2017 |
|
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
|
30 October 2017 |
|
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
|
25 October 2017 |